Wise Practice of Chinese Hemodialysis (WISHES)

Haemolyses and Related Conditions Clinical Trial

Official title:

Wise Practice of Chinese Hemodialysis (WISHES)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03001921
• Other study ID #: WISHES
• Status: Recruiting
• Start date: December 2013
• Est. completion date: December 2027

Study information

• Verified date: October 2020
• Source: Sun Yat-sen University
• Contact: Xueqing Yu, M.D. & Ph.D.
• Email: yuxq[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The investigators are registering all HD patients at recruited hospitals and developing a HD database in China. Patients will be follow-up every 3 months, and both baseline and follow-up information will be entered into the registration system. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Description:

The investigators are registering all end stage renal disease (ESRD) patients receiving hemodialysis (HD) treatment, and developing a HD database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum, urine, and access patency), complications, drug information and scores of quality of life at the baseline will be collected. Patients will be follow-up every 3 month, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), technical survival, kidney transplantation, transfer to peritoneal dialysis, hospitalization, access failure，etc. The patient survival, technical survival, patency rate of access, quality of life and residual renal function for HD patients will be compared using the HD database.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30000
• Est. completion date: December 2027
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

End stage renal disease patients receiving hemodialysis treatment.

Exclusion Criteria:

No

Related Conditions & MeSH terms

• Haemolyses and Related Conditions
• Hemolysis

Intervention

Other:
• No intervention
Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.

Locations

Country	Name	City	State
China	The 1st Affiliated Hospital, Sun Yet-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient survival of HD patients		10 years
Secondary	Quality of life evaluated using SF36 scale for HD patients		10 years
Secondary	Patency rate of access for HD patients		10 years